Alpha cell receptor for advanced glycation end products associate with glucagon expression in type 1 diabetes

被引:0
|
作者
Sherman S. Leung
Nataliya Lenchik
Clayton Mathews
Alberto Pugliese
Domenica A. McCarthy
Selena Le Bagge
Adam Ewing
Mark Harris
Kristen J. Radford
Danielle J. Borg
Ivan Gerling
Josephine M. Forbes
机构
[1] The University of Queensland (MRI-UQ),Glycation and Diabetes Complications, Mater Research Institute, Translational Research Institute (TRI)
[2] The University of Queensland,Faculty of Medicine
[3] Griffith University,School of Medicine and Dentistry
[4] Wesley Research Institute,Division of Endocrinology, Department of Medicine
[5] The Wesley Hospital,Division of Endocrinology, Department of Microbiology and Immunology, Department of Medicine, Diabetes Research Institute, Miller School of Medicine
[6] University of Tennessee Health Science Center,Translational Bioinformatics Group
[7] University of Miami,Queensland Diabetes Centre
[8] MRI-UQ,Cancer Immunotherapies Group
[9] TRI,undefined
[10] Mater Health Services,undefined
[11] MRI-UQ,undefined
[12] TRI,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Hypoglycemia in type 1 diabetes associates with changes in the pancreatic islet α cells, where the receptor for advanced glycation end products (RAGE) is highly expressed. This study compared islet RAGE expression in donors without diabetes, those at risk of, and those with type 1 diabetes. Laser-dissected islets were subject to RNA bioinformatics and adjacent pancreatic tissue were assessed by confocal microscopy. We found that islets from type 1 diabetes donors had differential expression of the RAGE gene (AGER) and its correlated genes, based on glucagon expression. Random forest machine learning revealed that AGER was the most important predictor for islet glucagon levels. Conversely, a generalized linear model identified that glucagon expression could be predicted by expression of RAGE signaling molecules, its ligands and enzymes that create or clear RAGE ligands. Confocal imaging co-localized RAGE, its ligands and signaling molecules to the α cells. Half of the type 1 diabetes cohort comprised of adolescents and a patient with history of hypoglycemia—all showed an inverse relationship between glucagon and RAGE. These data confirm an association between glucagon and islet RAGE, its ligands and signaling pathways in type 1 diabetes, which warrants functional investigation into a role for RAGE in hypoglycemia.
引用
收藏
相关论文
共 50 条
  • [41] Advanced glycation end products (AGEs) and the soluble receptor for AGE (sRAGE) in patients with type 1 diabetes and coeliac disease
    Bakker, S. F.
    Tushuizen, M. E.
    Gozutok, E.
    Ciftci, A.
    Gelderman, K. A.
    Mulder, C. J.
    Simsek, S.
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2015, 25 (02) : 230 - 235
  • [42] Effects of Resveratrol on Receptor for Advanced Glycation End Products (RAGE) Expression and Oxidative Stress in the Liver of Rats with Type 2 Diabetes
    Khazaei, Mohammad
    Karimi, Jamshid
    Sheikh, Nasrin
    Goodarzi, Mohammad Taghi
    Saidijam, Massoud
    Khodadadi, Iraj
    Moridi, Heresh
    PHYTOTHERAPY RESEARCH, 2016, 30 (01) : 66 - 71
  • [43] Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes
    K. C. B. Tan
    W. S. Chow
    A. W. K. Tso
    A. Xu
    H. F. Tse
    R. L. C. Hoo
    D. J. Betteridge
    K. S. L. Lam
    Diabetologia, 2007, 50 : 1819 - 1825
  • [44] ADVANCED GLYCATION END PRODUCTS AND THE SOLUBLE FORM OF THE AGE RECEPTOR IN PATIENTS WITH TYPE II DIABETES AND OSTEOARTHRITIS
    Thauerer, B.
    Kullich, W.
    Stritzinger, B.
    Kroell-Kalbhenn, A.
    Reimair, S.
    Salzer, A.
    Steinecker-Frohnwieser, B.
    OSTEOARTHRITIS AND CARTILAGE, 2022, 30 : S393 - S394
  • [45] Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes
    Tan, K. C. B.
    Chow, W. S.
    Tso, A. W. K.
    Xu, A.
    Tse, H. F.
    Hoo, R. L. C.
    Betteridge, D. J.
    Lam, K. S. L.
    DIABETOLOGIA, 2007, 50 (09) : 1819 - 1825
  • [46] Induction of receptor for advanced glycation end products by insufficient leptin action triggers pancreatic β-cell failure in type 2 diabetes
    Han, Dong
    Yamamoto, Yasuhiko
    Munesue, Seiichi
    Motoyoshi, So
    Saito, Hidehito
    Myat Thu Thu Win
    Watanabe, Takuo
    Tsuneyama, Koichi
    Yamamoto, Hiroshi
    GENES TO CELLS, 2013, 18 (04) : 302 - 314
  • [47] Receptor for advanced glycation end products is involved in impaired angiogenic response in diabetes
    Shoji, Takuhito
    Koyama, Hidenori
    Morioka, Tomoaki
    Tanaka, Shinji
    Kizu, Akane
    Motoyama, Kohka
    Mori, Katsuhito
    Fukumoto, Shinya
    Shioi, Atsushi
    Shimogaito, Noriko
    Takeuchi, Masayoshi
    Yamamoto, Yasuhiko
    Yonekura, Hideto
    Yamamoto, Hiroshi
    Nishizawa, Yoshiki
    DIABETES, 2006, 55 (08) : 2245 - 2255
  • [48] Expression of High Mobility Group Box 1 and Receptor for Advanced Glycation End Products in the Gingival Tissues of Periodontitis Patients with Type 2 Diabetes Mellitus
    Raj, Ramya
    Appukuttan, Devapriya
    Subramanian, Sangeetha
    Prakash, P. S. G.
    Crena, Jasmine
    TURKISH JOURNAL OF IMMUNOLOGY, 2023, 11 (02): : 74 - 92
  • [49] ADVANCED GLYCATION END PRODUCTS, SOLUBLE RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS AND RISK OF LIVER CANCER.
    Moy, K. A.
    Jiao, L.
    Freedman, N. D.
    Weinstein, S. J.
    Sinha, R.
    Virtamo, J.
    Albanes, D.
    Stolzenberg-Solomon, R. Z.
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2012, 175 : S103 - S103
  • [50] Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas
    Tomonori Sasahira
    Yoshihiko Akama
    Kiyomu Fujii
    Hiroki Kuniyasu
    Virchows Archiv, 2005, 446 : 411 - 415